Patents Issued in February 20, 2020
  • Publication number: 20200054690
    Abstract: A composition composed of xylooligosaccharide, arabinogalactan, inulin, Ganoderma lucidum beta glucan, insoluble yeast ? (1, 3/1, 6)-glucan, soluble oat ? (1,3/1, 4)-glucan, and insoluble dried Saccharomyces cerevisiae fermentate, with a Bacillus coagulans component, for use in improving or maintaining digestive health, weight and glucose balance and boosting immunity is provided.
    Type: Application
    Filed: April 10, 2018
    Publication date: February 20, 2020
    Inventor: Natarajan Ranganathan
  • Publication number: 20200054691
    Abstract: The present invention provides a Bifidobacterium lactis GKK2, a composition comprising thereof and its use for improving asthma, especially for lowering airway resistance, reducing levels of non-specific and specific IgE in serum, alleviating bronchoconstriction and increasing levels of GSH reductase in liver tissue interstitial fluid to improve allergic asthma.
    Type: Application
    Filed: August 15, 2019
    Publication date: February 20, 2020
    Applicant: GRAPE KING BIO LTD.
    Inventors: Chin-Chu CHEN, Yen-Lien CHEN, Shin-Wei LIN, Yen-Po CHEN, Ci-Sian WANG, Yu-Hsin HOU, Yang-Tzu SHIH, Ching-Wen LIN, Ya-Jyun CHEN, Jia-Lin JIANG
  • Publication number: 20200054692
    Abstract: The present invention provides a Bifidobacterium lactis having active substances, a composition comprising the same, and a method of promoting longevity using the same by subjecting the composition to a subject, thereby increasing Cisd2 gene expression, reducing damage of mitochondria, delaying aging-related symptoms including nerve degeneration and sarcopenia, and so on.
    Type: Application
    Filed: August 16, 2019
    Publication date: February 20, 2020
    Inventors: Chin-Chu CHEN, Yen-Lien Chen, Shih-Wei LIN, Yen-Po CHEN, Ci-Sian WANG, Yu-Hsin HOU, Yang-TZU SHIH, Ching-Wen LIN, Ya-Jyun CHEN, Jia-Lin JIANG
  • Publication number: 20200054693
    Abstract: Probiotic material to allow exposure of a baby born by non-natural childbirth, to bacterial flora that simulates that obtained during the natural birth process. A topical probiotic is described that is put on a baby when it is first born, and mimics the bacteria in the mother's vaginal canal. This topical probiotic re-creates the bacteria that the baby would have received had the baby been naturally born. In embodiments, a bacterial culture of the probiotic material includes at least Lactobacillus crispatus, Lactobacillus iners, Lactobacillus. jensenii, and Lactobacillus gasseri.
    Type: Application
    Filed: August 17, 2018
    Publication date: February 20, 2020
    Inventor: Scott Chamberlin
  • Publication number: 20200054694
    Abstract: The present invention relates to a topical composition of facilitating wound healing and reducing scars, which includes an inactivated culture of Lactobacillus species as an effective ingredient and can significantly facilitate wound healing as well as reducing scars, thereby can be applied to a method of facilitating wound healing and reducing scars.
    Type: Application
    Filed: August 13, 2019
    Publication date: February 20, 2020
    Inventors: Yi-Hsing Chen, Wan-Hua Tsai, Wen-Wei Chang, Chia-Hsuan Chou
  • Publication number: 20200054695
    Abstract: The present invention provides an active substance of Lactic Acid Bacteria, a composition comprising thereof and its use for promoting longevity, especially for increasing Cisd2 gene expression, reducing mitochondrial damage and delaying aging conditions such as nerve degeneration and sarcopenia.
    Type: Application
    Filed: August 15, 2019
    Publication date: February 20, 2020
    Applicant: GRAPE KING BIO LTD.
    Inventors: Chin-Chu CHEN, Yen-Lien CHEN, Shin-Wei LIN, Yen-Po CHEN, Ci-Sian WANG, Yu-Hsin HOU, Yang-Tzu SHIH, Ching-Wen LIN, Ya-Jyun CHEN, Jia-Lin JIANG
  • Publication number: 20200054696
    Abstract: The present invention provides an active substance of Lactic Acid Bacteria, a composition comprising thereof and its use for promoting longevity, especially for increasing Cisd2 gene expression, reducing mitochondrial damage and delaying aging conditions such as nerve degeneration and sarcopenia.
    Type: Application
    Filed: August 15, 2019
    Publication date: February 20, 2020
    Applicant: GRAPE KING BIO LTD.
    Inventors: Chin-Chu CHEN, Yen-Lien CHEN, Shin-Wei LIN, Yen-Po CHEN, Ci-Sian WANG, Yu-Hsin HOU, Yang-Tzu SHIH, Ching-Wen LIN, Ya-Jyun CHEN, Jia-Lin JIANG
  • Publication number: 20200054697
    Abstract: Embodiments of the disclosure encompass methods of treating or preventing an autoimmune disease in an individual. In particular cases, methods comprise administering for delivery to an individual a composition of microbiota. In certain cases, the composition comprises a population of one or more microbiota capable of producing one or more short-chain fatty acids.
    Type: Application
    Filed: April 11, 2018
    Publication date: February 20, 2020
    Inventors: Cintia S. De Paiva, Stephen C. Pflugfelder, Robert Allen Britton
  • Publication number: 20200054698
    Abstract: The respiratory microbiomes of neonates and those with bronchopulmonary disease have been characterized. Provided are probiotic compositions, which can include at least one living bacterial strain and at least one killed bacterial strain, that can comprise a combination of Lactobacilli species, 5 that when delivered to the bronchi or lungs of a patient can provide a reduction in the symptoms of a bronchopulmonary disease.
    Type: Application
    Filed: April 4, 2018
    Publication date: February 20, 2020
    Inventors: Charitharth Vivek Lal, Namasivayam Ambalavanan, Amit Gaggar, Casey Morrow
  • Publication number: 20200054699
    Abstract: A pharmaceutical composition comprising: a) an effective amount of one or more lytic bacteriophages specific against Fusobacterium nucleatum selected from Fnp?02-14, Fnp?11 and Fnn?107 or mixtures of them; and b) one or more pharmaceutically acceptable carrier and/or excipients. Method for preventing and/or treating diseases associated with Fusobacterium nucleatum and the use of the pharmaceutical composition for treating a disease associated with Fusobacterium nucleatum of the oral cavity such as V periodontal disease, among others.
    Type: Application
    Filed: November 9, 2016
    Publication date: February 20, 2020
    Inventors: Mauricio Waldemar BITTNER ORTEGA, Pamela Isabel MACHUCA VALENZUELA, Valeska Susana HERRERA SANHUEZA, Ignacio Andrés FUENTEVILLA MORGADO
  • Publication number: 20200054700
    Abstract: The present invention relates to Siphoviridae bacteriophage Ent-FAP-4 (accession number KCTC 12854BP), separated from nature, which is capable of specifically killing Enterococcus faecium and has a genome expressed by sequence number 1, a pharmaceutical composition, which comprises same as an active ingredient, and a method for preventing or treating diseases, induced by Enterococcus faecium, by means of the pharmaceutical composition.
    Type: Application
    Filed: January 11, 2018
    Publication date: February 20, 2020
    Inventors: Seong Jun Yoon, Soo Youn Jun, Hyoun Rok Paik, Jee Soo Son, Sang Hyeon Kang
  • Publication number: 20200054701
    Abstract: The present invention provides cannabis oil extracts and compositions thereof, including cannabis oil compositions containing vitamin E, and methods for preparing the extracts and compositions. In some embodiments, the present invention provides a method for preparing a cannabis oil extract comprising eluting cannabinoids from cannabis plant material with a solvent to produce an eluate, filtering the eluate with a filter to produce a filtrate, evaporating the solvent from the filtrate with a distiller to produce a distillate, and purging the distillate under conditions sufficient to remove residual solvent, thereby preparing the extract. In some embodiments, the method further includes mixing a quantity of vitamin E with the extract to produce a cannabis oil composition.
    Type: Application
    Filed: August 20, 2019
    Publication date: February 20, 2020
    Applicant: Constance Therapeutics, Inc.
    Inventors: Constance Finley, Luke McKee, Haley Poole Bestwick, Paul Roethle
  • Publication number: 20200054702
    Abstract: Provided are compositions and methods of forming a particulate material derived from a cannabis plant. The method includes introducing a component including at least one of: (i) a cannabinoid, and (ii) a terpene, to a polymer to produce a polymeric mixture. The component is dispersed in the polymeric mixture, which is then at least partially dehydrated to encapsulate the component within a polymeric material derived from the polymer. The polymeric material is water soluble. The dehydrated polymeric mixture is processed to form particulates comprising the component encapsulated within shells formed from the polymeric material.
    Type: Application
    Filed: May 1, 2018
    Publication date: February 20, 2020
    Inventor: Michael HELLER
  • Publication number: 20200054703
    Abstract: The present invention is directed to films made with edible polymers and containing a portion of finely ground olive leaf powder (OLP) suitable for preparing a hot or cold beverage and delivering an unexpectedly powerful quantity of natural anti-oxidant in the form of polyphenols.
    Type: Application
    Filed: July 24, 2017
    Publication date: February 20, 2020
    Inventors: Josephine Musco, James Rossman, Richard Fielder
  • Publication number: 20200054704
    Abstract: The present invention relates to novel black cumin extract compositions and a green process for making the composition. The black cumin extract composition of the invention can be used to treat anxiety, sleep and stress disorders along with significant effect on memory enhancement. The composition is available in oil and powder forms.
    Type: Application
    Filed: October 25, 2019
    Publication date: February 20, 2020
    Inventors: Krishnakumar Illathu MADHAVAMENON, Balu Paulose MALIAKEL, Sibi Perumbamkudiyil ITTIYAVIRAH, Kannan RAMALINGAM
  • Publication number: 20200054705
    Abstract: Provided is a composition comprising a plant extract. The plant extract includes a citrus extract and a green tea extract. The extract combination can effectively increase expression of GLUT4 gene.
    Type: Application
    Filed: April 3, 2018
    Publication date: February 20, 2020
    Inventors: Yung-Hsiang LIN, I-Hui CHEN, Kai-Wen KAN, Fu Chen LIU, Ciao-Ting CHEN
  • Publication number: 20200054706
    Abstract: The present invention relates to compositions comprising a water soluble tomato extract (WSTE) which may be used in maintaining cardiovascular health, lessening the risk of developing cardiovascular health problems, or reducing the likelihood of worsening an existing cardiovascular health problem in a subject exposed, or is at risk of exposure, to particulate air pollution.
    Type: Application
    Filed: November 2, 2017
    Publication date: February 20, 2020
    Applicant: Provexis Natural Products Limited
    Inventors: Bernd MUSSLER, Daniel RAEDERSTORFF, Nathalie RICHARD
  • Publication number: 20200054707
    Abstract: An oral dosage form or plurality of oral dosage forms comprising as active ingredients combinations of citric acid, magnesium citrate, phytin, pyridoxine, and musa is disclosed. The oral dosage form(s) is useful for inhibiting calcium oxalate crystal growth and for treating or inhibiting growth of kidney stones. Methods of inhibiting calcium oxalate crystal growth and of treating or preventing kidney stones are also disclosed.
    Type: Application
    Filed: October 25, 2019
    Publication date: February 20, 2020
    Inventors: Gregory K. Hayer, Brendan Magrab, Henry R. Wolfe
  • Publication number: 20200054708
    Abstract: The present invention relates to a composition and a method of utilizing Gastrodia elata extract or an adenosine analog to promote neurogenesis, wherein the G. elata extract includes gastrodin, gastrodigenin, parishins, N6-(4-hydroxybenzyl) adenosine (T1-11) and 4-hydroxybenzaldehyde. The G. elata extract of the present invention exhibits anti-aging activity on nerve cells and can induce neurogenesis in mouse hippocampus.
    Type: Application
    Filed: August 20, 2019
    Publication date: February 20, 2020
    Inventors: Yun-Lian Lin, Wei-Hsiang Hsu, Young-Ji Shiao
  • Publication number: 20200054709
    Abstract: This invention provides a method of colonic cleansing.
    Type: Application
    Filed: June 10, 2019
    Publication date: February 20, 2020
    Inventors: Dennis RIFF, Gary S. JACOB, Kunwar SHAILUBHAI, Patrick H. GRIFFIN
  • Publication number: 20200054710
    Abstract: Two peptides that can selectively bind to SEVI and block the enhanced infectivity that results from the interaction of SEVI with HIV. The two peptides comprise the amino acid sequences FEEIVQEIEDFLENLV (SEQ. ID NO: 1) and GIGAVLEVLTTGLPALISWIEEEEQQ (SEQ. ID. NO: 2). The peptides may be administered topically, either alone or in combination with other prophylactics, agents, etc.
    Type: Application
    Filed: November 1, 2019
    Publication date: February 20, 2020
    Applicant: SYRACUSE UNIVERSITY
    Inventor: Ivan V. Korendovych
  • Publication number: 20200054711
    Abstract: Methods of treating the effects of disruption of normal blood flow in the CNS in an individual subject in need thereof are provided according to aspects of the present invention which include administering a therapeutically effective dose of exogenous NeuroD1 to an area where normal blood flow has been disrupted. Compositions are provided including 1) a recombinant adeno-associated adenovirus expression vector comprising a glial cell specific promoter operably linked to a nucleic acid encoding a site-specific recombinase and 2) a recombinant adeno-associated adenovirus expression vector comprising a ubiquitous promoter operably linked to a nucleic acid encoding NeuroD1, wherein the nucleic acid encoding NeuroD1 is inverted and flanked by two sets of site-specific recombinase recognition sites such that action of the recombinase irreversibly inverts the nucleic acid encoding NeuroD1 such that NeuroD1 is expressed in a mammalian cell.
    Type: Application
    Filed: February 28, 2018
    Publication date: February 20, 2020
    Inventor: Gong Chen
  • Publication number: 20200054712
    Abstract: The present invention relates to Protoxin-II variants, polynucleotides encoding them, and methods of making and using the foregoing.
    Type: Application
    Filed: November 4, 2019
    Publication date: February 20, 2020
    Inventors: Mack FLINSPACH, Alan WICKENDEN, Ross FELLOWS, Qinghao XU, Andrew PIEKARZ
  • Publication number: 20200054713
    Abstract: The composition of the present invention can inhibit homologous human T cell reaction and the phenomenon of infiltration which reduces skin graft damage in vivo, thereby enabling prompt, rapid and effective graft rejection prevention or treatment effects at a low concentration. In addition, the present invention has advantages of successfully controlling in vivo human T cell reactions, as compared with conventional therapeutic agents, thus providing few side effects, the possibilities of local high-dose administration of therapeutic agents and potentially new treatments and prescriptions.
    Type: Application
    Filed: August 19, 2019
    Publication date: February 20, 2020
    Inventors: Je-Min CHOI, Sangho LIM
  • Publication number: 20200054714
    Abstract: Provided herein are variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and/or FGF21, and variants or fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.
    Type: Application
    Filed: August 6, 2019
    Publication date: February 20, 2020
    Inventors: Lei Ling, Darrin Anthony Lindhout
  • Publication number: 20200054715
    Abstract: Methods of stimulating collagen production, including stimulation of chondrocyte production, at the site of a defect. Methods include administering to the site of a defect at least two proteins from the group IL-1ra, sTNF-RI, sTNF-RII, IGF-I, EGF, HGF, PDGF-AB, PDGF-BB, VEGF, TGF-?1, and sIL-1RII.
    Type: Application
    Filed: October 28, 2019
    Publication date: February 20, 2020
    Inventors: Andrea Matuska, Krista Toler, Jennifer E. Woodell-May
  • Publication number: 20200054716
    Abstract: Methods and pharmaceutical compositions of a unique Biologic Response Modifier (BRM) that does not suppress the immune system, yet provides protection of beta cells in those with type 1 diabetes and those at risk for type 1 diabetes are described. The methods include utilization of BRMs in combination with islet neogenesis therapies, beta regeneration therapies, islet, beta cell or stem cell transplants, or devices housing islets, beta cells or stem cells for treatment and prevention of type 1 patients and related conditions. The compositions and methods provide for beta cell protection from autoimmune attack for prevention or delay in the onset of type 1 diabetes. The BRM may be used in conjunction with immunosuppressive agents. The BRM may also be used in other conditions found among patients with type 1 diabetes and their relatives for whom there is no treatment or current therapy is unsuccessful.
    Type: Application
    Filed: November 6, 2019
    Publication date: February 20, 2020
    Inventor: Claresa Levetan
  • Publication number: 20200054717
    Abstract: A suspension formulation of an insulinotropic peptide (e.g., glucagon-like peptide-1 (GLP-1) or exenatide) is described. The suspension formulation comprises (i) a non-aqueous, single-phase vehicle, comprising one or more polymer and one or more one solvent, wherein the vehicle exhibits viscous fluid characteristics, and (ii) a particle formulation comprising the insulinotropic peptide, wherein the peptide is dispersed in the vehicle. The particle formulation further includes a stabilizing component comprising one or more stabilizers, for example, carbohydrates, antioxidants, amino acids, and buffers. Devices for delivering the suspension formulations and methods of use are also described.
    Type: Application
    Filed: June 14, 2019
    Publication date: February 20, 2020
    Inventors: Thomas R. Alessi, Ryan D. Mercer, Catherine M. Rohloff, Bing Yang
  • Publication number: 20200054718
    Abstract: Application for MDR TNBC significantly increasing the efficacy of TNBC treatment and address a global health concern by blocking the ability of mitochondria to fuse together and with other organelles through a nanomedicine therapy. The development of a dual targeted nanomedicine therapy targeting the epidermal growth factor receptor on the surface of TNBC cancers cells and subcellular targeting of mitochondria through mitofusin 2 (MFN2) targeting (mitofusin mediates inter-mitochondrial fusion and fusion of mitochondria with the endoplasmic reticulum). The combination therapy delivers an MFN2-peptidepolymer construct for blocking MFN2 along with a low dose of BAM? (a BAX activator).
    Type: Application
    Filed: April 4, 2018
    Publication date: February 20, 2020
    Inventor: Lara S Milane
  • Publication number: 20200054719
    Abstract: According to the invention, a novel combination composition and method of treatment for thrombotic disorders, e.g., STEMI in ACS patients, is disclosed. The present invention relates to thrombin analogs, e.g., WE and E-WE thrombin analogs, in combination with fibrinolytics, e.g., tPA. In particular, E-WE thrombin analog and fibrinolytic combination therapy for inhibition of thrombin mediated TAFi activation and acceleration of tPA induced thrombolysis with E-WE thrombin. The present invention also relates to methods of treating a subject having a thrombotic or thromboembolic disorder by delivering the novel composition comprised of at least one antithrombotic thrombin analog and at least one fibrinolytic agent to the subject.
    Type: Application
    Filed: November 2, 2017
    Publication date: February 20, 2020
    Inventors: Erik Ian Tucker, Brandon Davis Markway, Michael Nikolaus Wallisch, Nora Green Verbout
  • Publication number: 20200054720
    Abstract: The present invention provides methods for large scale preparation of sterile stable liquid thrombin composition comprised of glycerol; stable liquid thrombin compositions; and hemostatic composition and kits. The present invention further provides hemostatic compositions comprised of liquid thrombin, glycerol and gelatin. Further provided herein is a method for the large-scale production of a sterile liquid thrombin composition comprised of glycerol.
    Type: Application
    Filed: August 8, 2019
    Publication date: February 20, 2020
    Inventors: Erez ILAN, Omri FAINGOLD, Sivan DORON
  • Publication number: 20200054721
    Abstract: This disclosure provides materials and methods for treating or preventing graft-versus-host-disease (GVHD) using protein C or activated protein C or a signaling-selective variant or mutant thereof.
    Type: Application
    Filed: October 20, 2017
    Publication date: February 20, 2020
    Inventors: Bruce R. Blazar, John H. Griffin, Ryan P. Flynn, Ranjeet K. Sinha
  • Publication number: 20200054722
    Abstract: The present invention provides methods for improving observed or determined efficacy by administration of agents to more severely diseased subjects, as contrasted with less severely diseased subjects. The present disclosure specifically demonstrates that, with respect to treatment of certain skin conditions, and particularly conditions associated with dysregulated and/or diseased skin cells, administration to more severely diseased subjects improves observed or determined efficacy.
    Type: Application
    Filed: October 28, 2019
    Publication date: February 20, 2020
    Inventor: Jonathan Edelson
  • Publication number: 20200054723
    Abstract: The invention provides humanized anti-Siglec-8 antibodies and their use in treating and preventing eosinophil-mediated disorders and/or mast cell-mediated disorders, as well as compositions and kits comprising the humanized anti-Siglec-8 antibodies.
    Type: Application
    Filed: May 17, 2019
    Publication date: February 20, 2020
    Applicant: Allakos Inc.
    Inventors: Christopher R. BEBBINGTON, Rustom FALAHATI, Carolina Rita SOUSA FERNANDES, David John MATTHEWS, Nenad TOMASEVIC, Jason WILLIAMS, John LEUNG
  • Publication number: 20200054724
    Abstract: The gist of the invention consists in the therapeutic vaccine for treatment of diabetes type 1 in children, which contains Treg cells CD3(+)CD4(+)CD25(high)CD127(?). Claimed too is the cell sorter used to produce the vaccine and the method of multiplying Treg cells in vitro.
    Type: Application
    Filed: October 23, 2019
    Publication date: February 20, 2020
    Inventors: Piotr Trzonkowski, Malgorzata Mysliwiec, Natalia Marek-Trzonkowska
  • Publication number: 20200054725
    Abstract: The compositions described herein include an epitope of a peptide that may elicit an immune response in a subject following administration. The compositions may comprise nucleic acids. The compositions may comprise peptides. The methods described herein include administering a composition comprising an epitope of a peptide to a subject in need thereof.
    Type: Application
    Filed: March 29, 2019
    Publication date: February 20, 2020
    Inventors: Mary L. Disis, Denise Cecil, Meredith Slota
  • Publication number: 20200054726
    Abstract: A cancer therapy composition and a method of cancer treatment by inducing humoral and cellular immune responses against cancer cells in a patient is provided. The method includes administering to the patient a therapeutically effective amount of a vaccine, wherein the vaccine includes at least one tumor-associated antigen, at least one immunostimulant, and at least one lipid capable of forming a multilamellar liposome, or non-lipid molecule capable of forming a vesicle or gel. A therapeutically effective amount of at least one cell-based immunotherapeutic agent is also administered to the patient before, after, or at the same time the vaccine is administered to the patient.
    Type: Application
    Filed: October 9, 2019
    Publication date: February 20, 2020
    Inventors: Mircea C. Popescu, Richard J. Robb
  • Publication number: 20200054727
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Application
    Filed: October 31, 2019
    Publication date: February 20, 2020
    Inventors: Andrea MAHR, Toni WEINSCHENK, Anita WIEBE, Oliver SCHOOR, Jens FRITSCHE, Harpreet SINGH
  • Publication number: 20200054728
    Abstract: Methods described herein relate to constructing therapeutic fusion-specific vaccine libraries, selecting a therapeutic fusion-specific vaccine for a cancer patient, and/or constructing a de novo therapeutic fusion-specific vaccine for patients having a gene fusion that is absent from a fusion-specific vaccine library.
    Type: Application
    Filed: November 1, 2019
    Publication date: February 20, 2020
    Applicant: BostonGene Corporation
    Inventors: Maksym Artomov, Feliks Frenkel, Igor Golubev, Olga Zolotareva
  • Publication number: 20200054729
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Application
    Filed: November 4, 2019
    Publication date: February 20, 2020
    Inventors: Andrea MAHR, Toni WEINSCHENK, Oliver SCHOOR, Jens FRITSCHE, Harpreet SINGH
  • Publication number: 20200054730
    Abstract: Systems and methods are presented that allow for selection of tumor neoepitopes that are then used to generate recombinant nucleic acids that encode one or more polytopes that are optimized for proper trafficking and processing. In preferred methods, the polytopes are encoded in a plasmid and/or a viral expression system for use as a therapeutic agent.
    Type: Application
    Filed: April 23, 2018
    Publication date: February 20, 2020
    Inventor: Kayvan NIAZI
  • Publication number: 20200054731
    Abstract: The present disclosure provides immunomodulatory compositions comprising heat-killed Caulobacter crescentus (HKCC). Immunomodulatory compositions of the present disclosure are useful for modulating an immune response in an individual. The present disclosure thus provides methods of modulating an immune response in an individual, involving administering an immunomodulatory composition comprising HKCC to the individual.
    Type: Application
    Filed: July 15, 2019
    Publication date: February 20, 2020
    Inventors: Babita AGRAWAL, Rakesh KUMAR
  • Publication number: 20200054732
    Abstract: The disclosure relates to a glycoconjugate vaccine conferring protection against Francisella tularensis infections and a method to manufacture a glycoconjugate antigen.
    Type: Application
    Filed: September 11, 2017
    Publication date: February 20, 2020
    Applicant: London School of Hygiene and Tropical Medicine
    Inventors: Brendan Wren, Jon Cuccui, Madeleine Moule
  • Publication number: 20200054733
    Abstract: The present invention provides immunogenic compositions having one or more polysaccharide-protein conjugates in which one or more polysaccharides from Streptococcus pneumoniae bacterial capsules are conjugated to a carrier protein in an aprotic solvent such as dimethylsulfoxide (DMSO). The present invention also provides methods for providing an enhanced immune response to a pneumococcal polysaccharide protein conjugate vaccine comprising administering to a human subject an immunogenic composition comprising polysaccharide-protein conjugates prepared in DMSO conditions.
    Type: Application
    Filed: February 20, 2018
    Publication date: February 20, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Jian He, John E. MacNair, William J. Smith, Michael A. Winters, Joseph G. Joyce, Chitrananda Abeygunawardana, Luwy Musey, Hari Pujar, Julie M. Skinner, Emily Wen, Patrick McHugh, John Michael Williams, Catherine Lancaster
  • Publication number: 20200054734
    Abstract: Isolated peptides comprising one or more antigenic sites of filovirus glycoprotein and methods of their use and production are disclosed. Nucleic acid molecules encoding the peptides are also provided. In several embodiments, the peptides can be used to induce an immune response to filovirus glycoprotein, such as Zaire ebolavirus glycoprotein, in a subject, for example, to treat or prevent infection of the subject with the virus.
    Type: Application
    Filed: October 31, 2017
    Publication date: February 20, 2020
    Applicant: The United States of America, as represented by the Secretary, Department Health and Human Service
    Inventor: Surender Khurana
  • Publication number: 20200054735
    Abstract: A vaccine composition and method of vaccination are provided useful for immunizing a subject against a rotavirus. The vaccines include rotavirus strains CDC-9 and CDC-66, fragments thereof, homologues thereof, or combinations thereof. Inventive vaccines may include a fragment of CDC-9, CDC-66, homologues thereof, or combinations thereof. Methods of inducing an immunological response are provided by administering an inventive vaccine.
    Type: Application
    Filed: November 1, 2019
    Publication date: February 20, 2020
    Applicant: The U.S.A., as represented by the Secretary, Department of Health and Human Services
    Inventors: Baoming Jiang, Roger I. Glass, Yuhuan Wang, Jon Gentsch
  • Publication number: 20200054736
    Abstract: Provided herein are, inter alia, methods and compositions including T cells expressing (i) a recombinant CAR protein which includes a peptide binding site and is capable of specifically binding cancer-specific antigens and (ii) a T cell receptor specific for a viral antigen (e.g., a CMV pp65 protein). The engineered T cells provided herein may be used in combination with a viral vaccine (e.g. cytomegalovirus (CMV) Triplex Vaccine) to treat a variety of cancers. The methods described herein also permit in viva expansion of CMV-specific CAR T cells, instead of or in addition to ex vivo expansion, avoiding excessive T cell exhaustion that results in some cases from ex vivo manufacturing.
    Type: Application
    Filed: October 19, 2017
    Publication date: February 20, 2020
    Inventors: John C. WILLIAMS, Christine BROWN, Don J. DIAMOND
  • Publication number: 20200054737
    Abstract: The disclosure relates to herpes simplex virus (HSV) ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
    Type: Application
    Filed: April 25, 2018
    Publication date: February 20, 2020
    Applicant: Modema TX, Inc.
    Inventors: Giuseppe Ciaramella, Shinu John, Andrew J. Bett, Danilo R. Casimiro, Dai Wang, Lan Zhang
  • Publication number: 20200054738
    Abstract: The present disclosure relates to improved oral immunotherapy methods for treating peanut allergy. The disclosure provides methods for treating a subject for a peanut allergy by an oral immunotherapy comprising an up-dosing phase and a maintenance phase. In certain embodiments, the methods comprise non-daily administration to the subject of a maintenance phase dose. In certain embodiments, the methods comprise administering a maintenance phase dose for more than 24 weeks. In other embodiments, the disclosure provides methods for reducing the risk of an allergic adverse event in a subject receiving an oral immunotherapy dosage therapy.
    Type: Application
    Filed: August 15, 2019
    Publication date: February 20, 2020
    Inventor: Daniel ADELMAN
  • Publication number: 20200054739
    Abstract: Methods for the production of immunogenic compositions containing a non-natural amino acid are disclosed. The non-natural amino acid can be a site for attachment of antigens, such as bacterial capsular polysaccharides, to make immunogenic conjugates. Bio-orthogonal attachment chemistry incorporated into the non-natural amino acids allows for more efficient and potent antigen presentation to the immune system, simplified purification, and more well-defined structure of these semi-synthetic immunogens.
    Type: Application
    Filed: July 1, 2019
    Publication date: February 20, 2020
    Inventors: Jeffery C. FAIRMAN, Jon H. HEINRICHS, Wei CHAN, Olivier Jean Gérard MARCQ, Christopher R. Behrens